Claims for Patent: 9,738,690
✉ Email this page to a colleague
Summary for Patent: 9,738,690
Title: | Polyoma virus JC peptides and proteins in vaccination and diagnostic applications |
Abstract: | The present invention relates to the field of vaccination or immunization, in particular therapeutic vaccination, and diagnosis. Pharmaceutical compositions and kits capable of eliciting a protective immune response against polyoma virus JC (JCV) are disclosed, which may be used e.g., for therapy or for prevention of progressive multifocal leukoencephalopathy (PML) and/or progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome (PML-IRIS). Individuals in danger of such PML or PML-IRIS may, e.g., be immuno-compromised or immunosuppressed patients or patients having an autoimmune disease eligible for immunosuppressive treatment. The invention also relates to compositions comprising at least one CD4+ epitope of a JCV protein and to therapeutic, prophylactic and diagnostic uses thereof. |
Inventor(s): | Jelcic; Ilijas (Zurich, CH), Martin; Roland (Zurich, CH), Schippling; Sven (Zurich, CH), Sospedra; Mireia (Zurich, CH), Yousef; Sara (Hamburg, DE) |
Assignee: | UNIVERSITAET ZUERICH (Zurich, CH) |
Application Number: | 14/234,065 |
Patent Claims: | 1. A method of treating progressive multifocal leukoencephalopathy (PML) or progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome
(PML-IRIS) in a subject, the method comprising: providing a VP1 protein of polyoma virus JC (JCV), administering the VP1 protein of JCV to the subject, and administering an TLR-7 agonist or an TLR-8 agonist, thereby treating progressive multifocal
leukoencephalopathy (PML) or progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome (PML-IRIS) in the subject.
2. The method as recited in claim 1, wherein only the TLR-7 agonist is administered. 3. The method as recited in claim 1, further comprising: administering imiquimod. 4. The method as recited in claim 1, further comprising: administering an adjuvant selected from the group consisting of MF59, aluminium hydroxide, calcium phosphate gel, lipopolysaccharides, oligonucleotide sequences with CpG motifs, stearyl tyrosine, DTP-GDP, DTP-DPP, threonyl-MDP, 7-allyl-8-oxoguanosine, glycolipid bay R1005, multi-antigen peptide system, polymerized haptenic peptides, bacterial extracts, and vit-A. 5. The method as recited in claim 1, wherein the subject has a congenital immunodeficiency, an acquired immunodeficiency resulting from a disease or pathological condition, or an acquired immunodeficiency resulting from a therapeutic intervention. 6. The method as recited in claim 5, further comprising: treating with an immunosuppressive antibody. 7. The method as recited in claim 6, wherein the immunosuppressive antibody is selected from the group consisting of natalizumab, efalizumab, rituximab, ocrelizumab and alemtuzumab. 8. The method as recited in claim 5, wherein the subject is afflicted with an autoimmune disease. 9. The method as recited in claim 8, wherein the autoimmune disease is multiple sclerosis. 10. The method as recited in claim 9, wherein the subject is to be treated with the antibody natalizumab. 11. The method as recited in claim 5, wherein the subject has a congenital immunodeficiency selected from the group consisting of idiopathic CD4+ lymphopenia and Hyper-IgE-Syndrome. 12. The method as recited in claim 5, wherein the subject has an acquired immunodeficiency resulting from a disease or pathological condition selected from the group consisting of AIDS, leukemia, lymphoma, multiple myeloma, infection with hepatitis virus B, and infection with hepatitis C. 13. The method as recited in claim 5, wherein the subject has an acquired immunodeficiency resulting from a therapeutic intervention, wherein the therapeutic intervention is selected from the group consisting of chemotherapy, radiation and immunosuppressive treatment. |
Details for Patent 9,738,690
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2031-07-22 |
Idec Pharmaceuticals Corp. | RITUXAN | rituximab | Injection | 103737 | 02/19/2002 | ⤷ Try a Trial | 2031-07-22 |
Genzyme Corporation | CAMPATH | alemtuzumab | Injection | 103948 | 05/07/2001 | ⤷ Try a Trial | 2031-07-22 |
Genzyme Corporation | LEMTRADA | alemtuzumab | Injection | 103948 | 11/14/2014 | ⤷ Try a Trial | 2031-07-22 |
Genzyme Corporation | CAMPATH | alemtuzumab | Injection | 103948 | 10/12/2004 | ⤷ Try a Trial | 2031-07-22 |
Genentech, Inc. | RAPTIVA | efalizumab | Injection | 125075 | 10/27/2003 | ⤷ Try a Trial | 2031-07-22 |
Biogen Inc. | TYSABRI | natalizumab | Injection | 125104 | 11/23/2004 | ⤷ Try a Trial | 2031-07-22 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.